- Home
- HMN vs AUPH Comparison
HMN vs AUPH Comparison
Compare HMN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HMN | AUPH |
|---|---|---|
| Founded | 1945 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1991 | 1999 |
Fundamental Metrics
Financial Performance| Metric | HMN | AUPH |
|---|---|---|
| Price | $44.35 | $15.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $46.75 | $17.25 |
| AVG Volume (30 Days) | 223.3K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 56.80 | N/A |
| EPS | ★ 3.95 | 0.55 |
| Revenue | ★ $1,675,600,000.00 | $265,808,000.00 |
| Revenue This Year | $7.38 | $21.22 |
| Revenue Next Year | $6.60 | $15.40 |
| P/E Ratio | ★ $11.05 | $28.39 |
| Revenue Growth | 5.44 | ★ 20.62 |
| 52 Week Low | $36.20 | $6.55 |
| 52 Week High | $48.33 | $16.48 |
Technical Indicators
Market Signals| Indicator | HMN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 60.37 |
| Support Level | $44.23 | $14.70 |
| Resistance Level | $46.42 | $16.48 |
| Average True Range (ATR) | 0.99 | 0.56 |
| MACD | -0.22 | -0.15 |
| Stochastic Oscillator | 35.27 | 63.20 |
Price Performance
Historical ComparisonAbout HMN Horace Mann Educators Corporation
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.